HCW Biologics (HCWB) Net Equity Issued and Repurchased (2020 - 2025)

HCW Biologics (HCWB) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $4.0 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased rose 1.43% year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.3 million (down 3.02% YoY) and the FY2025 annual result came in at $5.5 million, down 15.0% from the prior year.
• Net Equity Issued and Repurchased advanced to $4.0 million in Q4 2025, from $2.2 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $4.0 million in Q4 2025 to a low of $84.0 in Q3 2023.
• A 5-year average of $711071.6 and a median of $6907.0 in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased soared 131528.62% — and 2025, when it tumbled 99.93%.
• Tracing HCWB's Net Equity Issued and Repurchased over 5 years: stood at $6102.0 in 2021, then decreased by 4.44% to $5831.0 in 2022, then soared by 140.82% to $14042.0 in 2023, then soared by 28105.2% to $4.0 million in 2024, then advanced by 1.43% to $4.0 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $4.0 million (Q4 2025), $2.2 million (Q3 2025), and $48608.0 (Q2 2025), per Business Quant data.